相关实验视频
Updated: Jun 10, 2025
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
15.9K
沙利德化物可能准PPARα,对NASH进行预防和治疗活动
Xueru Chu1,2, Shousheng Liu3, Baozhen Qu4
1Department of Infectious Disease, Qingdao Municipal Hospital, School of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Frontiers in pharmacology
|October 17, 2024
概括
沙利德 (SDS) 通过调节自,亡,免疫和炎症,有效地预防和治疗非酒精性脂肪肝炎 (NASH). 这种天然化合物显示出作为未来肝脏疾病治疗剂的前景.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 非酒精性脂肪肝炎 (NASH) 是一种普遍的慢性肝病,缺乏有效的治疗方法.
- 化 (SDS) 是由 * Rhodiola rosea * 衍生而来的,具有强大的抗氧化和肝脏保护性质.
- 这项研究研究了SDS对甲素和胆缺乏 (MCD) 饮食诱导的NASH小鼠模型的影响.
研究的目的:
- 评估Salidroside (SDS) 对非酒精性脂肪肝炎 (NASH) 的预防和治疗潜力.
- 阐明NASH中SDS作用的潜在分子机制.
- 探索SDS作为NASH的潜在治疗剂.
主要方法:
- 在C57BL/6J小鼠中使用甲素和胆缺乏 (MCD) 饮食诱导NASH.
- 在NASH诱导期间或之后,为期4周的SDS (24mg/kg/天) 给药.
- 通过各种染色技术,显微镜,PCR,西式涂抹,ELISA和流细胞计等方法进行了 histopathological,脂质,原蛋白,自,亡,免疫细胞和炎症因子分析.
- 转录蛋白质组测序和分子对接以识别SDS目标.
主要成果:
- SDS证明了对饮食诱导的NASH具有显著的预防和治疗效果.
- 在SDS治疗上调自,下调亡,重新平衡免疫反应,并减少肝炎.
- 转录蛋白质组测序和分子对接确定了PPARα作为SDS的潜在分子标.
结论:
- 沙利德化物 (SDS) 通过调节肝脏自,亡和免疫路径,有效地改善了NASH.
- 这种PPAR途径与SDS的抗NASH效应有关.
- SDS代表了未来非酒精性脂肪肝炎药物开发的有希望的候选人.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
579
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
579
01:31Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K